- Stocks
- Consumer Cyclical
- NYSE: MED

Price (delayed)

$201.66

Market cap

$2.37B

P/E Ratio

15.75

Dividend/share

$5.39

EPS

$12.8

Enterprise value

$2.19B

Medifast is the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers scientifically developed products, clinically proven plans and the support of Coaches and a

The EPS has surged by 97% year-on-year and by 20% since the previous quarter

MED's net income has soared by 97% YoY and by 20% QoQ

Medifast's debt has soared by 100% from the previous quarter and by 71% YoY

The company's quick ratio fell by 13% QoQ and by 7% YoY

What are the main financial stats of MED

Market
Valuations
Earnings

Shares outstanding

11.73M

Market cap

$2.37B

Enterprise value

$2.19B

Price to earnings (P/E)

15.75

Price to book (P/B)

12.18

Price to sales (P/S)

1.86

EV/EBIT

11.15

EV/EBITDA

10.69

EV/Sales

1.73

Revenue

$1.27B

EBIT

$196.74M

EBITDA

$205.17M

Free cash flow

$129.65M

Per share
Balance sheet
Liquidity

EPS

$12.8

Free cash flow per share

$11.03

Book value per share

$16.55

Revenue per share

$108.16

TBVPS

$30.99

Total assets

$364.23M

Total liabilities

$169.55M

Debt

$20.52M

Equity

$194.69M

Working capital

$150.34M

Debt to equity

0.11

Current ratio

1.98

Quick ratio

1.28

Net debt/EBITDA

-0.84

Margins
Efficiency
Dividend

EBITDA margin

16.1%

Gross margin

74.4%

Net margin

11.8%

Operating margin

15.5%

Return on assets

49%

Return on equity

90.3%

Return on invested capital

1,914.8%

Return on capital employed

93.6%

Return on sales

15.5%

Dividend yield

2.67%

DPS

$5.39

Payout ratio

42.1%

How has the Medifast stock price performed over time

Intraday

1.2%

1 week

5.64%

1 month

-3.15%

1 year

36.96%

YTD

2.71%

QTD

4.68%

How have Medifast's revenue and profit performed over time

Revenue

$1.27B

Gross profit

$945.53M

Operating income

$196.76M

Net income

$150.47M

Gross margin

74.4%

Net margin

11.8%

The operating income has soared by 117% YoY and by 20% QoQ

MED's net income has soared by 97% YoY and by 20% QoQ

MED's revenue has surged by 67% year-on-year and by 16% since the previous quarter

Medifast's gross profit has soared by 67% YoY and by 17% from the previous quarter

What is Medifast's growth rate over time

What is Medifast stock price valuation

P/E

15.75

P/B

12.18

P/S

1.86

EV/EBIT

11.15

EV/EBITDA

10.69

EV/Sales

1.73

The EPS has surged by 97% year-on-year and by 20% since the previous quarter

The price to earnings (P/E) is 39% less than the 5-year quarterly average of 25.8 and 26% less than the last 4 quarters average of 21.2

The equity has soared by 67% YoY and by 11% from the previous quarter

MED's P/B is 19% below its last 4 quarters average of 15.0 but 3.2% above its 5-year quarterly average of 11.8

MED's revenue has surged by 67% year-on-year and by 16% since the previous quarter

The P/S is 28% lower than the 5-year quarterly average of 2.6 and 23% lower than the last 4 quarters average of 2.4

How efficient is Medifast business performance

The return on invested capital has dropped by 74% since the previous quarter

The ROA has increased by 33% YoY and by 7% from the previous quarter

MED's ROE is up by 31% YoY and by 6% QoQ

The return on sales has increased by 29% year-on-year and by 4% since the previous quarter

What is MED's dividend history

DPS

$5.39

Dividend yield

2.67%

Payout ratio

42.1%

Recent dividends

How did Medifast financials performed over time

The total assets is 115% greater than the total liabilities

The total assets has soared by 57% year-on-year and by 12% since the previous quarter

Medifast's total liabilities has increased by 47% YoY and by 12% QoQ

Medifast's debt is 89% less than its equity

Medifast's debt has soared by 100% from the previous quarter and by 71% YoY

Medifast's debt to equity has soared by 83% from the previous quarter and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.